drugset / Trial / NCT03460782

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

NCT03460782

Summary

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 1 mg/kg Intravenous